Harrow Health, Inc. (NASDAQ: HROW) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Harrow Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $29.52, Harrow Health, Inc. trades at 3.6x sales and 37.5x book value, with an EV/EBITDA of 79.5. Over the last twelve months it generated about $307M of revenue and a net loss of $29M. It runs a gross margin of 73.5%, an operating margin of 0.8% and a net margin of -9.4%. It shows return on equity of -90.8%, return on invested capital of 0.7% and a free cash flow yield of -1.8%. On the balance sheet: a debt-to-equity ratio of 10.31 and a current ratio of 2.29. Over the past 52 weeks the share price ranged from $25.76 to $54.85, with a beta of 0.24.
Harrow Health, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Harrow Health, Inc. (HROW) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 24.1% / 30% · (Cash+Inv) / Mkt Cap (36m) 6.19% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 24.1% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.19% / 33% · Receivables / Mkt Cap (36m) 12.8% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 24.1% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.19% / 33.33% · Receivables / Mkt Cap (24m) 12.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 66.8% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 19.5% / 33.33% · Receivables / Avg Assets (4Q) 28.9% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 66.1% / 33.33% · (Cash+ST Inv) / Total Assets 17.0% / 33.33% · (Cash+Recv) / Total Assets 52.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Harrow Health, Inc. (HROW) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Harrow Health, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Harrow Health, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.